|Videos|August 7, 2020
Expedited Programs for Drug Approvals
Advertisement
Pharmaceutical Executive’s Lisa Henderson interviews Todd Phillips, PharmD, of Cardinal Health Regulatory Sciences about FDA’s expedited programs and key elements to consider before using this pathway.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Trending on PharmExec
1
Senate Democrats Expand Efforts to Expose Details of MFN Pharma Deals
2
Novo Nordisk Responds to FDA’s Warning Letter Regarding 2025 PADE Inspection
3
FDA Grants Priority Review to Enhertu as Treatment for Patients with HER2-positive Early Breast Cancer
4
FDA Approves Leucovorin Without a Clinical Trial for Cerebral Folate Transport Deficiency: Report
5